Early Identification of Malignant Brain Edema in laRge Artery oCclusive Stroke After Endovascular Therapy (EMBRACE Study)
Launched by ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL · Jun 6, 2024
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
The EMBRACE Study is a clinical trial that aims to develop and test a new method for predicting a serious condition called malignant brain edema in patients who have suffered a large artery blockage in the brain and have undergone a specific treatment known as endovascular thrombectomy. This condition can cause dangerous swelling in the brain, and the researchers hope to identify patients at high risk for this complication early on, so they can receive better care.
To participate in the study, individuals must be at least 18 years old and have had a stroke within the last 24 hours. They should have undergone certain imaging tests that show the type of blockage, and they need to be treated within the study parameters. Participants will receive regular follow-ups for three months after their treatment. It's important to note that people with certain severe health issues or poor-quality imaging may not be eligible. This study is currently looking for volunteers and is open to all genders.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • (1)Age \> 18 years old; (2)Onset of stroke to hospital admission \< 24 hours; (3)Admission with a head CT scan ruling out hemorrhage; (4)Patients undergoing CT perfusion scan before treatment; (5)Confirmation of internal carotid artery (ICA) or middle cerebral artery (MCA) occlusion or tandem occlusion by Digital Subtraction Angiography (DSA) and subsequent EVT; (6)complete 3-months follow-up.
- Exclusion Criteria:
- • (1)Poor quality of preoperative CT perfusion imaging; (2)Posterior circulation occlusion or isolated anterior cerebral artery occlusion; (3)Presence of other severe diseases such as malignant tumors, severe organ failure, or other life-threatening conditions with an expected survival period of less than 90 days; (4)Incomplete imaging and clinical data.
About Zhejiang Provincial People's Hospital
Zhejiang Provincial People's Hospital is a leading medical institution located in Hangzhou, China, renowned for its commitment to advancing healthcare through research and clinical excellence. As a prominent clinical trial sponsor, the hospital integrates cutting-edge medical research with state-of-the-art patient care, facilitating innovative studies across various therapeutic areas. With a team of experienced medical professionals and researchers, Zhejiang Provincial People's Hospital aims to contribute significantly to the development of new treatments and therapies, ensuring the highest standards of ethical practices and patient safety in all its clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported